Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017; 16: 35-47
Опыт внедрения алгоритма эмпирической антибактериальной терапии при развитии фебрильной нейтропении в Центре детской гематологии/онкологии
https://doi.org/10.24287/1726-1708-2017-16-3-35-47Аннотация
Список литературы
1. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H.. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106 (10): 2258-66.
2. Mikulska M., Viscoli C., Orasch C., Livermore D.M., Averbuch D., Cordonnier C., et al. Aetiology and resistance in bacteriaemias among adult and paediatric haematology and cancer patients. J infec 2014; 68: 321-31.
3. Lyman G.H., Rolston K.V.I. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J oncol pract 2010; 6 (3): 149-52.
4. Averbuch D., Orasch C., Cordonnier C., Livermore D.M., Mikulska M., Viscoli C., et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference of Infections in Luekemia. Нaematol 2013; 98 (12): 1826-35.
5. Antimicrobial resistance global report on surveillance, 2014. WHO Report, www.who.int/drugresistance/documents/AMR_report_Web_slide_set.pdf.
6. Behnke M., Hansen S., Leistner R., Diaz L.A., Gropmann A., Sohr D., et al. Nosocomial infection and antibiotic use. Dtsch Arztebl Int 2013; 110 (38): 627-33.
7. Flowers C.R., Seidenfeld J., Bow E.J., Karten C., Gleason C., Hawley D.K., et al. Antimicrobial prophycaxis and outpatient management of fever and neutropenia in adults treated for malignancy: american society of clinical oncology clinical practice guidline. Am soc clin oncol 2012, www.asco.org/guedlines/outpatient.
8. Lehrnbecher T., Phillips R., Alexander S., Alvaro F., Carlesse F., Fisher B., et al. Guidlenes for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Сlin Оncol 2012; 30 (35): 4427-38.
9. Freifield A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Clinical practice guidline for use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. CID 2011; 52: 57-93.
10. Viscoli C., Varnier O., Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology and risk stratification. CID 2005; 4 (40): 240-2.
11. Tissot F., Agrawai S., Pagano L., Petrikkos G., Groll A.H., et al. ECIL-6 Guidelines for the Treatment of Invasive Candidiasis, Aspergillosis and Mucormycosis in Liekemia and Hematopoietic Stem Cell Transplant Patients. Hematol 2017; 102: 433-44.
12. Klastersky J., Awada A., Paesmans M., Aoun M. Febrile neutropenia: a critical review of the initial management. CID 2004; 39 (1): 32-7.
13. Hakim H., Flynn P.M., Knapp K.M., Srivastava D.K., Gaur A.H. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009; 31 (9): 623-9.
14. Tam C.S., O'Reilly M., Andresen D., Lingaratnam S., Kelly A., Burbury K., et al. Use of empiric antimicrobial therapy in neutripenic fever. Intern Med J 2011; 41: 90-101.
15. Simon A., Furtwängler R., Graf N., Laws H.J., Voigt S., Piening B., et al. Surveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on? GMS Hyg Infect Control 2016, 11: 1-23.
16. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., et al. Surviving sepsis campain: international guidlines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39 (2): 165-228.
17. Worth L.J., Lingaratnam S., Taylor A., Hayward H.M., Morrissey S., Cooney J., et al. Use of risk stratification to guide ambulatory management of neutropenic fever. Int Med J 2011; 41b: 82-9.
18. Orasch C., Averbuch D., Mikulska M., Cordonnier C., Livermore D.M., Gyssens I.C., et al. Discontinuation of empirical antibiotic therapy in neutripenic leukaemia patients with fever of unknown origin is ethical. Clin Microbiol Infect 2015; 21: e25-e27.
19. Trecarichi E.M., Tumbarello M., Spanu T., Caira M., Fianchi L., et al. Incidence and clinical impact of extended-spectrum--lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia Coli in patients with hematological malignancies. J Infect 2009; 58 (4): 299-307.
20. Bassetti M., Poulakou G., Timsit J.-F. Focus on antimicrobial use in the era of antimicrobial resistance in ICU. Intensive Care Med 2016; 42 (6): 955-8.
21. Morrissey C., Gilroy N., Macesic N., Walker P., Nanda-Rajah M., et al. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014 .Intern Med J 2014; 44: 1298-314.
22. Groll A.H., Werner C., Tebbe J., Solopova G., Becker K., et al. Pulmonale Infectionen in der pädiatrischen Hämatologie und Oncologie. Monatsschr Kinderheilkd 2011; 159: 233-41.
23. Ruhnke M., Schwartz S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol 2016; 7 (6): 345-59.
24. Cordonnier C., Pautas C., Maury S., Vekhoff A., Farhat H., et al. Empirical versus antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-51.
25. Dolton M.J., Ray J.E., Chen Sh.A., Ng K., Pont L.G., McLachlan A.J. Multicenter study of voriconasol pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 59 (9): 4793-9.
26. Dolton M.J., Ray J.E., Chen Sh.A., Ng K., Pont L.G., McLachlan A.J. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56 (11): 5503-10.
27. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000387/WC500049756.pdf.
28. De Pauw B., Walsh T.J., Donnelly J.P., Stevens E.E., Edwards J.E., et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12): 1813-21.
29. Patterson T.F., Thompson G.R., Denning D.W., Fishman J.A., Hadley S., et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016; 63 (4): e1-e60.
30. Cornely O., Rikan-Akdagli S., Dannaoui E., Groll A., Lagrou, K., et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20 (Suppl. 3): 5-26.
31. Солопова Г.Г, Рачков В.Е., Ускова Н.Г., Оганесян Р.С., Коновалов Д.М., Новичкова Г.А. Мукормикоз гастроинтестинальной локализации у пациента с острым миелобластным лейкозом. Вопросы гематологии/онкологии и иммунопатологии в педиатрии, 2014; 13 (4): 69-74.
32. Cordonnier C., Rovira M., Maertens J., Olavarria E., Faucher C., et al. Voriconazole for secondary prophylaxis of invasive fungal infection in allogeneic stem cell transplant recipients: Results of the VOSIFI study. Haematol 2010; 95: 1762-8.
33. Солопова Г.Г., Сацук А.В., Щемелин-ская Ю.Л., Пирумова В.П., Пимено-ва О.В., Масчан А.А., Новичкова Г.А. Организация службы инфекционного контроля в клинике детской гематологии/онкологии. Доктор.ру, Педиатрия Онкогематология, 2015, 10 (111): 14-22.
34. HeusselC., KauczorH., HeusselG., FischerB., BegrichM., etal. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999; 17: 796-805.
35. Новичкова Г.А., Горонкова О.В., Балашов Д.Н., Байдильдина Д.Д., Жарикова Л.И. и др. Диагностика, клиника и лечение инвазивного аспергиллеза у детей с приобретенной апластической анемией: анализ 20 собственных случаев. Гематология и трансфузиология 2005; 1.
36. Alvarez R., Lopez Cortes L.E., Molina J., Cisneros J.M., Pachon J. Oprimizing the clinical use of vancomycin. Antimicrob Agents Chemother 2016; 60 (5): 2601-9.
Pediatric Hematology/Oncology and Immunopathology. 2017; 16: 35-47
Implementation of the algorithm of empirical antibacterial therapy for febrile neutropenia in the Сenter of pediatric hematology/oncology
https://doi.org/10.24287/1726-1708-2017-16-3-35-47Abstract
Febrile neutropenia is a life-threatening condition that requires the immediate administration of broad-spectrum antibiotics. On the other hand, the most serious problem of medicine is the continuously growing resistance of microorganisms to antibiotics. It is known that the main reason for this phenomenon is the irrational and excessive use of antibacterial drugs in the hospital. To make treatment of infectious complications more effective, optimize use of antibiotics and reduce resistance of microorganisms in Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology (Center) the algorithm for empirical antibacterial therapy of febrile neutropenia was developed. Analysis of early results showed a reduction in the consumption of all classes antibiotics in the intensive care unit (ICU) a year after the start of the algorithm. After three years, it was possible to reduce the consumption of β-lactams, fluoroquinolones and linezolid throughout the Center. When analyzing the level of resistance to antibiotics, its decrease for such pathogens as Kl. pneumoniae, Ps. aeruginosae and Ent. Cloacae was revealed. To obtain other results of the algorithm, further detailed analysis is needed.
References
1. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H.. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106 (10): 2258-66.
2. Mikulska M., Viscoli C., Orasch C., Livermore D.M., Averbuch D., Cordonnier C., et al. Aetiology and resistance in bacteriaemias among adult and paediatric haematology and cancer patients. J infec 2014; 68: 321-31.
3. Lyman G.H., Rolston K.V.I. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J oncol pract 2010; 6 (3): 149-52.
4. Averbuch D., Orasch C., Cordonnier C., Livermore D.M., Mikulska M., Viscoli C., et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference of Infections in Luekemia. Naematol 2013; 98 (12): 1826-35.
5. Antimicrobial resistance global report on surveillance, 2014. WHO Report, www.who.int/drugresistance/documents/AMR_report_Web_slide_set.pdf.
6. Behnke M., Hansen S., Leistner R., Diaz L.A., Gropmann A., Sohr D., et al. Nosocomial infection and antibiotic use. Dtsch Arztebl Int 2013; 110 (38): 627-33.
7. Flowers C.R., Seidenfeld J., Bow E.J., Karten C., Gleason C., Hawley D.K., et al. Antimicrobial prophycaxis and outpatient management of fever and neutropenia in adults treated for malignancy: american society of clinical oncology clinical practice guidline. Am soc clin oncol 2012, www.asco.org/guedlines/outpatient.
8. Lehrnbecher T., Phillips R., Alexander S., Alvaro F., Carlesse F., Fisher B., et al. Guidlenes for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Slin Oncol 2012; 30 (35): 4427-38.
9. Freifield A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Clinical practice guidline for use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. CID 2011; 52: 57-93.
10. Viscoli C., Varnier O., Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology and risk stratification. CID 2005; 4 (40): 240-2.
11. Tissot F., Agrawai S., Pagano L., Petrikkos G., Groll A.H., et al. ECIL-6 Guidelines for the Treatment of Invasive Candidiasis, Aspergillosis and Mucormycosis in Liekemia and Hematopoietic Stem Cell Transplant Patients. Hematol 2017; 102: 433-44.
12. Klastersky J., Awada A., Paesmans M., Aoun M. Febrile neutropenia: a critical review of the initial management. CID 2004; 39 (1): 32-7.
13. Hakim H., Flynn P.M., Knapp K.M., Srivastava D.K., Gaur A.H. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009; 31 (9): 623-9.
14. Tam C.S., O'Reilly M., Andresen D., Lingaratnam S., Kelly A., Burbury K., et al. Use of empiric antimicrobial therapy in neutripenic fever. Intern Med J 2011; 41: 90-101.
15. Simon A., Furtwängler R., Graf N., Laws H.J., Voigt S., Piening B., et al. Surveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on? GMS Hyg Infect Control 2016, 11: 1-23.
16. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., et al. Surviving sepsis campain: international guidlines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39 (2): 165-228.
17. Worth L.J., Lingaratnam S., Taylor A., Hayward H.M., Morrissey S., Cooney J., et al. Use of risk stratification to guide ambulatory management of neutropenic fever. Int Med J 2011; 41b: 82-9.
18. Orasch C., Averbuch D., Mikulska M., Cordonnier C., Livermore D.M., Gyssens I.C., et al. Discontinuation of empirical antibiotic therapy in neutripenic leukaemia patients with fever of unknown origin is ethical. Clin Microbiol Infect 2015; 21: e25-e27.
19. Trecarichi E.M., Tumbarello M., Spanu T., Caira M., Fianchi L., et al. Incidence and clinical impact of extended-spectrum--lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia Coli in patients with hematological malignancies. J Infect 2009; 58 (4): 299-307.
20. Bassetti M., Poulakou G., Timsit J.-F. Focus on antimicrobial use in the era of antimicrobial resistance in ICU. Intensive Care Med 2016; 42 (6): 955-8.
21. Morrissey C., Gilroy N., Macesic N., Walker P., Nanda-Rajah M., et al. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014 .Intern Med J 2014; 44: 1298-314.
22. Groll A.H., Werner C., Tebbe J., Solopova G., Becker K., et al. Pulmonale Infectionen in der pädiatrischen Hämatologie und Oncologie. Monatsschr Kinderheilkd 2011; 159: 233-41.
23. Ruhnke M., Schwartz S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol 2016; 7 (6): 345-59.
24. Cordonnier C., Pautas C., Maury S., Vekhoff A., Farhat H., et al. Empirical versus antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-51.
25. Dolton M.J., Ray J.E., Chen Sh.A., Ng K., Pont L.G., McLachlan A.J. Multicenter study of voriconasol pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 59 (9): 4793-9.
26. Dolton M.J., Ray J.E., Chen Sh.A., Ng K., Pont L.G., McLachlan A.J. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56 (11): 5503-10.
27. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000387/WC500049756.pdf.
28. De Pauw B., Walsh T.J., Donnelly J.P., Stevens E.E., Edwards J.E., et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12): 1813-21.
29. Patterson T.F., Thompson G.R., Denning D.W., Fishman J.A., Hadley S., et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016; 63 (4): e1-e60.
30. Cornely O., Rikan-Akdagli S., Dannaoui E., Groll A., Lagrou, K., et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20 (Suppl. 3): 5-26.
31. Solopova G.G, Rachkov V.E., Uskova N.G., Oganesyan R.S., Konovalov D.M., Novichkova G.A. Mukormikoz gastrointestinal'noi lokalizatsii u patsienta s ostrym mieloblastnym leikozom. Voprosy gematologii/onkologii i immunopatologii v pediatrii, 2014; 13 (4): 69-74.
32. Cordonnier C., Rovira M., Maertens J., Olavarria E., Faucher C., et al. Voriconazole for secondary prophylaxis of invasive fungal infection in allogeneic stem cell transplant recipients: Results of the VOSIFI study. Haematol 2010; 95: 1762-8.
33. Solopova G.G., Satsuk A.V., Shchemelin-skaya Yu.L., Pirumova V.P., Pimeno-va O.V., Maschan A.A., Novichkova G.A. Organizatsiya sluzhby infektsionnogo kontrolya v klinike detskoi gematologii/onkologii. Doktor.ru, Pediatriya Onkogematologiya, 2015, 10 (111): 14-22.
34. HeusselC., KauczorH., HeusselG., FischerB., BegrichM., etal. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999; 17: 796-805.
35. Novichkova G.A., Goronkova O.V., Balashov D.N., Baidil'dina D.D., Zharikova L.I. i dr. Diagnostika, klinika i lechenie invazivnogo aspergilleza u detei s priobretennoi aplasticheskoi anemiei: analiz 20 sobstvennykh sluchaev. Gematologiya i transfuziologiya 2005; 1.
36. Alvarez R., Lopez Cortes L.E., Molina J., Cisneros J.M., Pachon J. Oprimizing the clinical use of vancomycin. Antimicrob Agents Chemother 2016; 60 (5): 2601-9.
